Document is current
Any future updates will be listed below
-
Authors
Uson, P. L. S. Jr.
Kunze, K. L.
Golafshar, M. A.
Botrus, G.
Riegert-Johnson, D.
Boardman, L.
Borad, M. J.
Ahn, D.
Sonbol, M. B.
Kahn, A.
Klint, M.
Esplin, E. D.
Nussbaum, R. L.
Stewart, A. K.
Bekaii-Saab, T.
Samadder, N. J. https://orcid.org/0000-0001-7182-5569
-
Funding
Funding for this research was provided by:
Mayo Transform the Practice Grant
Center for Individualized Medicine, Mayo Clinic
Desert Mountain Members’ CARE Foundation
David and Twila Woods Foundation
Faculty Career Development Award from the Gerstner Foundation
- License Information
-
More Information
Article History
Received: 14 September 2021
Accepted: 11 January 2022
First Online: 5 February 2022
Declarations
:
: NJS is a consultant for Jansen Research and Development and Cancer Prevention Pharmaceuticals. EDE and RLN are employees and stockholders of Invitae. RLN is also a consultant for Pfizer and a consultant and stockholder in Genome Medical and Maze Therapeutics. No other authors have a conflict of interest to disclose.
